It was in with the new and out with the old Jan. 3 as the gavel came down on the first session of the 119th U.S. Congress.

Balt Group SAS recently secured €355 million (US$365 million) in funding to refinance its debt, invest in research and accelerate its growth. The French-based provider of interventional neuroradiology ...

The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this ...

Zhongzhi Pharmaceutical Holdings Ltd. made a $3 million investment in a series A financing round of stem cell therapy developer Gabaeron Inc. Dec. 21, expected to help propel Gabaeron’s preclinical ...

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...

The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven ...

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

A recent study by researchers from Fudan University and Tau Cambridge Ltd. explored a novel therapeutic strategy that combines targeting CD47 with ANGPTL3, a key regulator of lipid metabolism, as a ...

Atavistik Bio Inc. has entered into a research collaboration with Pfizer Inc. to accelerate the discovery of novel precision allosteric therapeutics for unmet medical needs. Under the collaboration, ...

Innovent Biologics Inc. has entered into a collaboration and exclusive license agreement with F. Hoffmann-La Roche Ltd. to advance the development of IBI-3009, a novel DLL3-targeted antibody-drug ...

Major depressive disorder (MDD) notched another late-stage failure in the form of Neumora Therapeutics Inc.’s data from the phase III Koastal-1 study, the first of three replicant trials in the ...